10238-28-5

Usage

Uses

1. Used in Enzyme Assays:
P-NITROPHENYL ALPHA-D-XYLOPYRANOSIDE is used as a chromogenic substrate for alpha-xylosidase, an enzyme that catalyzes the hydrolysis of xylo-oligosaccharides and xylo-polysaccharides. The substrate's ability to change color upon enzymatic action makes it a valuable tool for monitoring enzyme activity, studying enzyme kinetics, and detecting enzyme deficiencies in various research and diagnostic applications.
2. Used in Pharmaceutical Research:
In the pharmaceutical industry, P-NITROPHENYL ALPHA-D-XYLOPYRANOSIDE is used as a key intermediate in the synthesis of various drugs and drug candidates. Its unique chemical structure allows for the development of novel therapeutic agents targeting specific biological pathways.
3. Used in Analytical Chemistry:
P-NITROPHENYL ALPHA-D-XYLOPYRANOSIDE is employed as a reference compound and a standard in analytical chemistry for the calibration of instruments and the development of new methods for the detection and quantification of xylo-oligosaccharides and xylo-polysaccharides.
4. Used in Food Industry:
In the food industry, P-NITROPHENYL ALPHA-D-XYLOPYRANOSIDE can be used as a component in the development of novel food additives or as a tool for the analysis of xylose-containing compounds in various food products.
5. Used in Environmental Science:
P-NITROPHENYL ALPHA-D-XYLOPYRANOSIDE can be utilized in environmental science for the assessment of microbial degradation of xylose-containing compounds in soil, water, and other ecosystems, contributing to a better understanding of carbon cycling and nutrient availability in these systems.

InChI:InChI=1/C11H13NO7/c13-8-5-18-11(10(15)9(8)14)19-7-3-1-6(2-4-7)12(16)17/h1-4,8-11,13-15H,5H2/t8-,9+,10-,11-/m1/s1

Upstream product

• 100-02-7 4-nitro-phenol 
• 14227-90-8 2,3,4-tri-O-acetyl-α-L-arabinopyranosyl bromide 
• 16673-34-0 5-chloro-2-methoxy-N-(4-sulfamoylphenethyl)benzamide 
• 3173-53-3 Cyclohexyl isocyanate 
• 64-04-0 phenethylamine 
• 108-91-8 cyclohexylamine 
• 56379-88-5 cyclohexylcarbamic acid phenyl ester 
• 223253-87-0 4-[2-(2,2,2-trifluoroacetamido)ethyl]benzenesulfonyl chloride 
• 458-85-5 2,2,2-trifluoro-N-(2-phenylethyl)acetamide 
• 33924-54-8 4-(2-[(5-chloro-2-methoxyphenyl)formamido]ethyl)benzene-1-sulfonyl chloride 
• 29568-33-0 2-methoxy-5-chlorobenzoyl chloride 
• 3438-16-2 5-chloro-2-methoxybenzoic acid 
• 33924-49-1 DK₁₃ 
• 201230-82-2 carbon monoxide 

Downstream Products

• 1089715-92-3 p-amidophenyl-α-L-arabinopyranoside 
• 643758-65-0 p-Nitrophenyl 2,3-di-O-benzoyl-α-L-arabinopyranoside 
• 100-02-7 4-nitro-phenol 

Relevant academic research and scientific papers

Total Synthesis of Glipizide and Glibenclamide in Continuous Flow

Glipizide and glibenclamide remain some of the widely prescribed antidiabetic sulfonylurea drugs for the treatment of type 2 diabetes mellitus. Herein the authors report on an isocyanate-free synthetic procedure towards the preparation of these on demand drugs at multigram scale using continuous flow technology. The safety concern over the use of isocyanates in most of the existing synthetic routes was dealt with in this present work by using N-carbamates synthesised in situ from activation of amines with chloroformates as safer alternatives. An overall yield of 80–85 % was obtained for the semi-telescoped steps within 10 min total residence time.

Synthesis method of glibenclamide

The invention discloses a synthesis method of glibenclamide, which includes the steps of: 1) protection of amino groups with trichloroacetic anhydride; 2) sulfonation; 3) sulfo-amidation; 4) amidation: performing a reaction to 5-chloro-2-methoxybenzoic acid with N,N-carbonyl diimidazole and performing a reaction to the product with a compound (III) under effect of a second acid-binding agent; 5) addition: adding the second acid-binding agent and crown ether, in catalytic amount, to perform an addition reaction to a compound (IV) with cyclohexyl isocyanate to prepare the glibenclamide. The method is high in yields in all steps, wherein residue of impurities is effectively reduced during processes of protection, deprotection, acid treatment, alkali treatment and water-adding separation of the substrate. According to the method, a phase-transfer catalyst is matched with the second acid-binding agent, so that compatibility between the isocyanate and the compound (IV) is effectively increased, and the nucleophilic reaction is carried out more completely. The produced product is higher in purity.

A sulfonyl urea, sulfonamide ethyl ester preparation method of compound (by machine translation)

The description relates to a compound of formula (I) compound of the preparation method, wherein formula (II) with a compound represented by formula (III) as shown in the catalysis of palladium catalyst, under a carbon monoxide atmosphere, reacts in a solvent to obtain the compound. The invention related to the method of the reaction do not require strict-free conditions, does not need a high pressure carbon monoxide atmosphere, convenient and simple to operate, to a functional group and has very high power density and universality, the catalyst consumption is very small, the cost of reaction is very low, and can be widely used for preparing sulfonyl urea compound. R1 - SO2 - NH - CO - X (R3 )n - R2 (I) R1 - SO2 - R4 (II) HX (R3 )n - R2 (III) wherein X is O or N; n is 0 or 1; when X is when O, n=0; when X is when N, n=1; R1 Selected from aryl, heteroaryl, alkyl, alkenyl or alkynyl; R2 Selected from aryl, heteroaryl, alkyl, alkenyl or alkynyl; R3 Is selected from H, R2 , Or R3 And R2 A ring of connection; R4 For N3 Or a halogen atom; when R4 For nails halogen original, system also comprises a sodium azide. (by machine translation)

Synthesis technology of glibenclamide

The invention provides a novel synthesis technology of a glibenclamide bulk pharmaceuticals. The glibenclamide product is finally prepared by taking sulfamide as a starting raw material through the four steps of a secondary condensation reaction, a compounding reaction, a dealcoholization reaction and refining. The technology has the advantages of being high in yield, low in purity, easy and convenient to operate, suitable for industrialized production and the like.

Design and Performance Validation of a Conductively Heated Sealed-Vessel Reactor for Organic Synthesis

A newly designed robust and safe laboratory scale reactor for syntheses under sealed-vessel conditions at 250 °C maximum temperature and 20 bar maximum pressure is presented. The reactor employs conductive heating of a sealed glass vessel via a stainless steel heating jacket and implements both online temperature and pressure monitoring in addition to magnetic stirring. Reactions are performed in 10 mL borosilicate vials that are sealed with a silicone cap and Teflon septum and allow syntheses to be performed on a 2-6 mL scale. This conductively heated reactor is compared to a standard single-mode sealed-vessel microwave instrument with respect to heating and cooling performance, stirring efficiency, and temperature and pressure control. Importantly, comparison of the reaction outcome for a number of different synthetic transformations performed side by side in the new device and a standard microwave reactor suggest that results obtained using microwave conditions can be readily mimicked in the operationally much simpler and smaller conventionally heated device.

Product-Derived Bimetallic Palladium Complex Catalyzes Direct Carbonylation of Sulfonylazides

A novel product-derived bimetallic palladium complex catalyzes a sulfonylazide-transfer reaction with the σ-donor/π-acceptor ligand CO, and is advantageous given its broad substrate scope, high efficiency, and mild reaction conditions (atmospheric pressure of CO at room temperature). This methodology provides a new approach to sulfonylureas, which are present in both pharmaceuticals and agrochemicals. The synthesis of Glibenclamide on a gram scale further revealed the practical utility of this procedure. Mechanistically, the generation of a bridged bimetallic palladium species derived from the product sulfonylurea is disclosed as the crucial step for this catalytic cycle.

Mechanosynthesis of pharmaceutically relevant sulfonyl-(thio)ureas

We demonstrate the first application of mechanochemistry to conduct the synthesis of sulfonyl-(thio)ureas, including known anti-diabetic drugs tolbutamide, chlorpropamide and glibenclamide, in good to excellent isolated yields by either stoichiometric base-assisted or copper-catalysed coupling of sulfonamides and iso(thio)cyanates. the Partner Organisations 2014.

Voltammetric and spectrophotometric study on the complexation of glibenclamide with β-cyclodextrin

The formation of an inclusion complex of glibenclamide (GL) with β-cyclodextrin (β-CD) in an aqueous ethanolic buffer solution of pH 7.0 has been investigated by UV spectrophotometry and differential pulse voltammetry and its stability constant is determined to be 855 and 354.15 M-1, respectively. The phase solubility profile, based on the spectrophotometric absorbance's variations, was classified as AL-type, indicating the formation of 1:1 stoichiometric inclusion complex of glibenclamide with β-CD with a stability constant value, KS, of 846 M-1.

USE OF SUBSTITUTED 2 PHENYLBENZIMIDAZOLES AS MEDICAMENTS

The present invention relates to the use of a substituted 2-phenylbenzimidazole of formula I wherein R1, R2, R3, R 4, R5 and m have the meanings given in the claims, for the preparation of a medicament for the treatment or prevention of diseases involving glucagon receptors, as well as new compounds of formula I wherein R1 is a group of formula

Combinations comprising dipeptidylpeptidase-iv inhibitor

The invention relates to a combination which comprises a DPP-IV inhibitor and at least one further antidiabetic compound, preferably selected from the group consisting of insulin signalling pathway modulators, like inhibitors of protein tyrosine phosphatases (PTPases), non-small molecule mimetic compounds and inhibitors of glutamine-fructose-6-phosphate amidotransferase (GFAT), compounds influencing a dysregulated hepatic glucose production, like inhibitors of glucose-6-phosphatase (G6Pase), inhibitors of fructose-1,6-bisphosphatase (F-1,6-BPase), inhibitors of glycogen phosphorylase (GP), glucagon receptor antagonists and inhibitors of phosphoenolpyruvate carboxykinase (PEPCK), pyruvate dehydrogenase kinase (PDHK) inhibitors, insulin sensitivity enhancers, insulin secretion enhancers, α-glucosidase inhibitors, inhibitors of gastric emptying, insulin, and α2-adrenergic antagonists, for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of conditions mediated by dipeptidylpeptidase-IV (DPP-IV), in particular diabetes, more especially type 2 diabetes mellitus, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, metabolic acidosis, ketosis, arthritis, obesity and osteoporosis; and the use of such combination for the cosmetic treatment of a mammal in order to effect a cosmetically beneficial loss of body weight.